European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"Prognostic value of [18F]FET-PET in diffuse low-grade (grade 2) gliomas after the 2021 classification of CNS tumors.","authors":"Michael Müther,Lorenz König,Philipp Backhaus,Walter Stummer,Oliver M Grauer,Michael Schäfers,Philipp Schindler,Matthias Weckesser,Wolfgang Roll","doi":"10.1007/s00259-025-07543-1","DOIUrl":"https://doi.org/10.1007/s00259-025-07543-1","url":null,"abstract":"PURPOSEAmino acid PET with [18F]-fluoroethylthyrosine ([18F]FET-PET) is frequently utilized in gliomas. Most studies on prognostication based on amino acid PET comprise mixed cohorts of brain tumors with low- and high-grade features. The objective of this study was to assess the potential prognostic value of [18F]FET-PET-based markers in the group of grade 2 adult-type diffuse gliomas, as defined by the WHO CNS 2021 classification.METHODSRetrospectively, all therapy-naive patients having undergone [18F]FET-PET before maximal safe resection of grade II / 2 gliomas over a time of 2012-2022 were included. Diagnoses were updated according to the WHO CNS 2021 classification. [18F]FET-PET were quantitatively evaluated, including dynamic PET acquisition if available. The primary outcome measure was progression-free survival (PFS), progression was defined by RANO 2.0 criteria.RESULTSIn the cohort of WHO grade 2 gliomas, 57 (69%) patients were diagnosed with astrocytoma, IDH-mutant. Twenty-six (31%) patients were diagnosed with oligodendroglioma, IDH-mutant and 1p/19q-codeleted. Quantitative PET uptake parameters (TBRmax, TBRmean, BTV) were significantly higher in oligodendroglioma compared to astrocytoma (p < 0.001). In all patients, Cox regression analysis of clinical and imaging parameters did not identify any factor that significantly impacted PFS. In the subgroup of astrocytoma without adjuvant treatment, for patients with TBRmax above 1.9 PFS was significantly shorter (p < 0.001).CONCLUSIONPreoperative [18F]FET-PET can provide prognostic information in distinct subgroups of diffuse low-grade gliomas not having undergone adjuvant therapies. Following external validation, preoperative [18F]FET-PET may possibly be employed as a decision-support tool to inform the choice of adjuvant therapies in astrocytoma.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"44 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145025438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[18F]MFBG PET/CT imaging of myocardial sympathetic innervation in healthy controls and patients with parkinson's disease: dosimetry and pharmacokinetics.","authors":"Louis Versweyveld,Aline Delva,Marie Cohilis,Christophe M Deroose,Donatienne Van Weehaeghe,Michel Koole,Wim Vandenberghe,Koen Van Laere","doi":"10.1007/s00259-025-07517-3","DOIUrl":"https://doi.org/10.1007/s00259-025-07517-3","url":null,"abstract":"PURPOSECardiac noradrenergic denervation visualized by meta-[123I]iodobenzylguanidine ([123I]MIBG) imaging supports the diagnosis of Parkinson's disease (PD). Recently, meta-[18F] fluorobenzylguanidine ([18F]MFBG) PET demonstrated favorable imaging characteristics compared with [123I]MIBG scintigraphy for neuroendocrine tumors. We assessed [18F]MFBG dosimetry and myocardial pharmacokinetics in healthy controls and PD patients.METHODSFor dosimetry, three controls underwent sequential whole-body [18F]MFBG PET/CT up to 6 hours postinjection. Five controls and three PD patients underwent 120-min dynamic cardiac [18F]MFBG PET/CT and two static [123I]MIBG SPECT/CT scans with planar scintigraphy, at 15 min and 3-4 h postinjection. An aortic image-derived input function with population-based radiometabolite corrections was validated against arterial sampling to derive myocardial distribution volume (VT) using a 2-tissue compartment model (2TCM). [18F]MFBG VT was assessed for time-stability and compared to heart-to-mediastinum ratio (HMR) for [18F]MFBG and [123I]MIBG.RESULTSMean effective dose was 23.1±2.6 μSv/MBq. [18F]MFBG exhibited rapid blood pool clearance and cardiac uptake, with VT of 35.1±10.6 mL/cm3 in controls and 5.9±1.6 mL/cm3 in PD. 2TCM VT from 30-min dynamic PET datasets starting at tracer injection showed strong agreement (mean difference -1.3 mL/cm3 and LoA=-7.1 mL/cm3 to 4.5 mL/cm3) and correlation (R2=0.97, p<0.001) to 2TCM VT from full 120-min datasets. [18F]MFBG HMR correlated the same to [18F]MFBG VT (ρ=0.88, p=0.007) for 10-30-min as for 100-120-min postinjection time intervals. [123I]MIBG HMR correlated more strongly to [18F]MFBG VT at 3-4h (ρ=0.9, p<0.005) compared to at 15-min (ρ=0.69, p=0.069) postinjection.CONCLUSION[18F]MFBG PET is a feasible and safe imaging modality for non-invasive and simplified quantification of myocardial sympathetic innervation.CLINICAL TRIAL REGISTRATIONClinicalTrials.gov https://clinicaltrials.gov/study/NCT06120049.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"15 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145017745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synthesis, preclinical evaluation and clinical application of a novel heterodimeric tracer 68Ga-pentixafor-c(RGDfK) for PET-CT imaging.","authors":"Fan Jia,Dayong Hou,Han Zhang,Huihui You,Liang Cheng,Wei Liu,Yue Zhao,Xinyue Yang,Xinglu Zhou,Miao Yu,Geng Hu,Chenxu Guo,Hongxue Meng,Wanhai Xu,Kezheng Wang","doi":"10.1007/s00259-025-07549-9","DOIUrl":"https://doi.org/10.1007/s00259-025-07549-9","url":null,"abstract":"OBJECTIVECXCR4 and integrin αvβ3 play important roles in tumor biology and are highly expressed in multiple types of tumors. This study aimed to synthesize, preclinically evaluate, and clinically validate a novel dual-targeted PET imaging probe 68Ga-pentixafor-c(RGDfK) for its potential in imaging tumors.METHODSThe effects of 68Ga-pentixafor-c(RGDfK) on cell viability, targeting specificity, and affinity were assessed in the U87MG cells. Micro-PET/CT imaging and biodistribution studies were conducted in U87MG tumor-bearing BALB/c nude mice to evaluate the probe's in vivo pharmacokinetics. A prospective analysis was conducted on patients who underwent both 68Ga-pentixafor-c(RGDfK) PET/CT and 18F-FDG PET/CT. The results obtained from the two imaging modalities were compared.RESULTSIn vitro, 68Ga-pentixafor-c(RGDfK) showed higher uptake activity, targeting specificity, and affinity in U87MG cells than 68Ga-pentixafor. In vivo, tumor uptake was higher than in normal tissues (P < 0.05), with renal excretion and low hepatobiliary excretion. Clinical results indicated that 68Ga-pentixafor-c(RGDfK) PET/CT had higher sensitivity, specificity, and accuracy in diagnosing primary and metastatic lesions compared to 18F-FDG PET/CT (93.1% vs. 74.7%, 79.2% vs. 62.5%, 90.1% vs. 72.1%, and 93.2% vs. 74.5%, 84.7% vs. 78%, 89.7% vs. 75.9%). The tumor-to-background ratio (TBR) at 120 min delayed scanning was significantly higher than at 60 min (P < 0.05).CONCLUSION68Ga-pentixafor-c(RGDfK) PET/CT demonstrated good safety and clinical feasibility in diagnosing tumors, particularly in differentiating benign and malignant lesions when 18F-FDG PET/CT results are uncertain.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"11 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145017756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of multiparameter [68Ga]Ga-DOTA-FAPI-04 PET/MR imaging biomarkers for patients with advanced pancreatic cancer.","authors":"Zeyu Zhang,Shiwei Guo,Weiwei Su,Guixia Pan,Yiting Wang,Yuchao Li,Kai Cao,Hui Jiang,Lu Zhang,Chao Cheng,Haojun Chen,Gang Jin,Changjing Zuo","doi":"10.1007/s00259-025-07491-w","DOIUrl":"https://doi.org/10.1007/s00259-025-07491-w","url":null,"abstract":"PURPOSEIn this retrospective study, whether [68Ga]Ga-DOTA-FAPI-04 PET/MR imaging biomarkers can predict the progression-free survival (PFS) and overall survival (OS) of patients with advanced pancreatic cancer was investigated.METHODSFifty-one patients who underwent [68Ga]Ga-DOTA-FAPI-04 PET/MR scans before first-line chemotherapy were recruited. Imaging biomarkers, including the maximum tumor diameter, minimum apparent diffusion coefficient (ADC), maximum and mean standardized uptake values (SUVmax and SUVmean), fibroblast activation protein- (FAP-) positive tumor volume (FTV and W-FTV) and total lesion FAP expression (TLF and W-TLF), were recorded for primary and whole-body tumors. A subgroup analysis of 28 patients with obstructive inflammation was performed, and the maximum and mean standardized uptake values (D-SUVmax and D-SUVmean), FAP-positive uptake volume (D-FTV), and total FAP expression (D-TLF) in the distal pancreas were assessed. Kaplan-Meier analysis and the Cox proportional hazards model were used to assess the relationships between these imaging biomarkers and PFS/OS.RESULTSSUVmax was negatively correlated with the ADC (r = -0.288, P = 0.041), whereas tumor length was positively correlated with the FTV, TLF, W-FTV, and W-TLF (r = 0.311-0.508, P < 0.05). The median PFS was not reached in patients with a W-TLF ≤ 516.09 but was 91 days in patients with a W-TLF > 516.09 (P < 0.001). Univariate and multivariate Cox regression analyses identified W-TLF as an independent predictor of PFS (P = 0.001, hazard ratio (HR) = 4.949). The TNM stage, tumor length, ADC value, SUVmax, TLF, W-FTV, and W-TLF were significantly associated with OS (P < 0.05). Multivariate analysis further confirmed that tumor length, ADC, and W-TLF were independent predictors of OS (P < 0.05). A subgroup analysis including 28 patients with obstructive pancreatitis revealed that TNM stage, tumor length, W-FTV, W-TLF, D-FTV, and D-TLF were significantly associated with OS (P < 0.05). The multivariate analysis further identified W-TLF and D-FTV as independent predictors of OS (P < 0.05).CONCLUSIONS[68Ga]Ga-DOTA-FAPI-04 PET/MRI biomarkers are associated with the PFS and OS of pancreatic cancer patients. Both the ADC and W-TLF are independent risk factors for patients with advanced disease. Increased fibroblast activity, driven by cancer-induced inflammation, may influence long-term survival outcomes following adjuvant therapy. These biomarkers have potential for guiding future clinical trials, enabling personalized treatment strategies, and ultimately improving the management and prognosis of patients with pancreatic cancer.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"32 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145017742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantification of monoamine oxidase B expression with 11C-SL25.1188 for imaging reactive astrocytes in patients with Alzheimer's disease.","authors":"Kiwamu Matsuoka,Yuhei Takado,Yasuyuki Kimura,Akihiko Kitamura,Hitomi Kitamura,Mayuka Kanda,Michihiro Takada,Maiko Ono,Harutsugu Tatebe,Hironobu Endo,Shin Kurose,Keisuke Takahata,Yoko Ikoma,Masanori Ichihashi,Masaki Oya,Kosei Hirata,Hideki Matsumoto,Asumi Orihara,Naomi Kokubo,Yuko Kataoka,Hong Zhang,Kenji Tagai,Chie Seki,Hitoshi Shinotoh,Tatsuya Kikuchi,Masanori Ichise,Hiroshi Shimizu,Akiyoshi Kakita,Kazunori Kawamura,Ming-Rong Zhang,Hitoshi Shimada,Kenji Nagao,Takahiko Tokuda,Makoto Higuchi","doi":"10.1007/s00259-025-07542-2","DOIUrl":"https://doi.org/10.1007/s00259-025-07542-2","url":null,"abstract":"PURPOSEAstrocyte reactivation can be assessed using positron emission tomography (PET) ligands targeting monoamine oxidase B (MAO-B). 11C-SL25.1188 binds reversibly to MAO-B, allowing precise density measurements, but requires invasive arterial sampling. This study aimed to develop a simplified, noninvasive method to quantify MAO-B with 11C-SL25.1188 PET in Alzheimer's disease (AD).METHODSSix patients with mild cognitive impairment (MCI), five patients with AD, and six healthy controls (HCs) underwent 11C-SL25.1188 PET scans. The distribution volume ratios (DVRs) were calculated and compared using two methods: the original multilinear reference tissue model (MRTMO) and the Logan plot. Changes in MAO-B densities, plasma glial fibrillary acidic protein (GFAP) levels, and abnormal protein aggregation were examined among subjects.RESULTSA strong agreement was observed between the DVRs estimated using MRTMO and those obtained with the Logan plot (r2 = 0.89), with the cerebellar cortex used as the reference region. This region was selected based on its similar total distribution volume values and comparable MAO-B levels between patients with AD and HCs. Patients with MCI showed higher DVRs in the parietal cortex compared to those with moderate AD. Moreover, patients with moderate AD had higher plasma GFAP levels than HCs but similar levels to patients with MCI.CONCLUSIONMAO-B density in patients with MCI/AD can be accurately estimated by calculating DVRs using a simplified quantification method that does not require arterial blood sampling. The estimated MAO-B density shows an increase that peaks at the MCI stage, suggesting early astrocyte reactivation in the progression of AD pathology.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"62 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145003287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence-assisted assessment of metabolic response to tebentafusp in metastatic uveal melanoma: a long axial field-of-view [18F]FDG PET/CT study.","authors":"Christos Sachpekidis,Devayani Machiraju,Dimitrios Stefanos Strauss,Leyun Pan,Annette Kopp-Schneider,Lars Edenbrandt,Antonia Dimitrakopoulou-Strauss,Jessica C Hassel","doi":"10.1007/s00259-025-07504-8","DOIUrl":"https://doi.org/10.1007/s00259-025-07504-8","url":null,"abstract":"PURPOSETebentafusp has emerged as the first systemic therapy to significantly prolong survival in treatment-naïve HLA-A*02:01 + patients with unresectable or metastatic uveal melanoma (mUM). Notably, a survival benefit has been observed even in the absence of radiographic response. This study aims to investigate the feasibility and prognostic value of artificial intelligence (AI)-assisted quantification and metabolic response assessment of [18F]FDG long axial field-of-view (LAFOV) PET/CT in mUM patients undergoing tebentafusp therapy.MATERIALS AND METHODSFifteen patients with mUM treated with tebentafusp underwent [18F]FDG LAFOV PET/CT at baseline and 3 months post-treatment. Total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG) were quantified using a deep learning-based segmentation tool On the RECOMIA platform. Metabolic response was assessed according to AI-assisted PERCIST 1.0 criteria. Associations between PET-derived parameters and overall survival (OS) were evaluated using Kaplan-Meier survival analysis.RESULTSThe median follow up (95% CI) was 14.1 months (12.9 months - not available). Automated TMTV and TLG measurements were successfully obtained in all patients. Elevated baseline TMTV and TLG were significantly associated with shorter OS (TMTV: 16.9 vs. 27.2 months; TLG: 16.9 vs. 27.2 months; p < 0.05). Similarly, higher TMTV and TLG at 3 months post-treatment predicted poorer survival outcomes (TMTV: 14.3 vs. 24.5 months; TLG: 14.3 vs. 24.5 months; p < 0.05). AI-assisted PERCIST response evaluation identified six patients with disease control (complete metabolic response, partial metabolic response, stable metabolic disease) and nine with progressive metabolic disease. A trend toward improved OS was observed in patients with disease control (24.5 vs. 14.6 months, p = 0.08). Circulating tumor DNA (ctDNA) levels based on GNAQ and GNA11 mutations were available in 8 patients; after 3 months Of tebentafusp treatment, 5 showed reduced Or stable ctDNA levels, and 3 showed an increase (median OS: 24.5 vs. 3.3 months; p = 0.13). Patients with increasing ctDNA levels exhibited significantly higher TMTV and TLG on follow-up imaging.CONCLUSIONAI-assisted whole-body quantification of [1⁸F]FDG PET/CT and PERCIST-based response assessment are feasible and hold prognostic significance in tebentafusp-treated mUM. TMTV and TLG may serve as non-invasive imaging biomarkers for risk stratification and treatment monitoring in this malignancy.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"163 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145002800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of bone marrow disease on hematologic toxicity and response to [177Lu]Lu-PSMA-617 therapy: insights from PSMA-PET/CT imaging.","authors":"Nuno Borges,Meryam Losee,Mofei Liu,Su-Chun Cheng,Arda Könik,Jolivette Ritzer,Andrew Wolanski,Thomas S C Ng,Atish D Choudhury,Mary-Ellen Taplin,Praful Ravi,Heather Jacene","doi":"10.1007/s00259-025-07541-3","DOIUrl":"https://doi.org/10.1007/s00259-025-07541-3","url":null,"abstract":"PURPOSEDespite the effectiveness of [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC), hematologic toxicity remains a concern, particularly in patients with bone metastases. This study evaluated whether the extent, intensity, and heterogeneity of bone disease on pretreatment PSMA-PET/CT were associated with hematologic toxicity, PSA response, and overall survival (OS) in mCRPC patients treated with [177Lu]Lu-PSMA-617.METHODSThis retrospective study included 96 mCRPC patients who underwent pretreatment PSMA-PET/CT and received standard-of-care [177Lu]Lu-PSMA-617. Hematologic toxicity, PSA responses, and OS were analyzed in relation to quantitative PET parameters, including tumor volume, SUVmean, and heterogeneity of PSMA uptake in bone metastases.RESULTSClinically significant hematologic toxicity occurred in 19 patients (19.8%). Treatment discontinuation was more likely in those with a significantly higher (p = 0.007) percentage of total bone volume with PSMA-avid disease (median 28% vs. 1.7%). Those requiring dose delays or reductions (median 21% vs. 1.5%), blood transfusions (median 21% vs. 1.4%), and platelet transfusions (median 32% vs. 1.8%) also exhibited higher median percentages of total bone volume involvement (all p < 0.01). Patients with more heterogeneous PSMA uptake had lower PSA50 response rates than those with more homogeneous uptake (30.3% vs. 64.5%, p = 0.002). A > 50% difference between PSMA-low and PSMA-high bone disease was associated with significantly shorter OS (p < 0.001).CONCLUSIONExtensive PSMA-avid bone involvement was associated with increased hematologic toxicity in mCRPC treated with [177Lu]Lu-PSMA-617. Greater heterogeneity in PSMA uptake correlated with lower PSA50 response and OS but not hematologic toxicity. Careful patient selection and monitoring are needed, particularly in those with widespread bone disease.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"64 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144995912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sentinel node detection and imaging concordance in Early-Stage ovarian cancer: A MELISA trial analysis of tracer, timing, and intraoperative gamma camera.","authors":"Nuria Agusti,Pilar Paredes,Sergi Vidal-Sicart,Federico Migliorelli,Cristina Celada,Nuria Carreras,Francisco Campos,Tiermes Marina,Inmaculada Romero,Ariel Glickman,Andrea Fritsch,Nahir Navarro,Pere Fuste,Aureli Torne,Berta Diaz-Feijoo","doi":"10.1007/s00259-025-07535-1","DOIUrl":"https://doi.org/10.1007/s00259-025-07535-1","url":null,"abstract":"PURPOSETo evaluate the detection rate of sentinel lymph node (SLN) mapping in early-stage ovarian cancer using [99mTc]Tc-nanocolloid and indocyanine green (ICG), and the added value of an intraoperative gamma camera.METHODSThis was a prospective single-center trial of 63 patients with suspected early-stage epithelial ovarian cancer who underwent SLN mapping with combined tracers. [99mTc]Tc-nanocolloid was injected into the ovarian ligaments before adnexectomy, and if malignancy was confirmed on intraoperative frozen section, ICG was administered after adnexectomy in immediate staging cases. SLNs were identified using a handheld gamma probe, the gold standard, and a portable gamma camera for radiotracer localization, alongside near-infrared imaging for ICG. We calculated SLN detection rates for each tracer and concordance between the tracers (reflecting the impact of injection timing), including identification of the same SLN- as well as between detection modalities. Cohen's κ and PABAK were used to assess concordance between detection modalities. Patients with confirmed malignancy underwent complete pelvic and aortic lymphadenectomy.RESULTSAmong 63 patients, sentinel lymph nodes (SLNs) were detected in 79.4% using [99mTc]Tc-nanocolloid. In the 30 patients who also received ICG, the combined use of both tracers achieved a detection rate of 93.3%, with higher detection in the aortic region compared to the pelvic region (83.3% vs. 43.3%). The intraoperative gamma camera showed 83.3% concordance with the gamma probe, including 87.5% concordance in the aortic region and 66.7% in the pelvic region. Among patients who received both tracers, 14 had drainage in at least one region by both, and 12 of these (85.7%) showed concordant detection of the same SLN. Concordance was 100% in re-staging and 77.8% in immediate surgeries.CONCLUSIONSLN mapping in ovarian cancer using a dual tracer approach is feasible and yields a higher detection rate than single tracers. The gamma camera identified SLN localization mainly in aortic regions. This combination may improve nodal staging in early ovarian cancer and reduce the need for systematic lymphadenectomy. Post-adnexectomy injection is a practical alternative to injection before adnexectomy for immediate surgeries, although caution is needed due to potential variations in lymphatic drainage.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"33 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144995883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cranial glucose metabolic patterns across prodromal and clinical parkinson's disease revealed by ¹⁸F-FDG PET.","authors":"Weizhao Lu, Tianbin Song, Ying Zhou, Qiaoling Zeng, Jing Li, Bixiao Cui, Jie Lu","doi":"10.1007/s00259-025-07533-3","DOIUrl":"10.1007/s00259-025-07533-3","url":null,"abstract":"<p><strong>Purpose: </strong>Bone plays pivotal roles in glucose homeostasis of the human body. Parkinson's disease (PD) is accompanied by metabolic dysfunction and increased risks of bone diseases. Nevertheless, whether PD affects bone glucose metabolism remains unknown. This study aimed to assess cranial glucose metabolism in different stages of PD using brain ¹⁸F-fludeoxyglucose positron emission tomography (¹⁸F-FDG PET).</p><p><strong>Methods: </strong>This prospective cross-sectional study included 190 participants, including 34 controls, 32 prodromal PD (pPD), 50 de novo PD (dnPD) and 74 medicated PD (mPD) patients. mPD patients were further separated into 3 stages: early-, middle- and late-stage PD patients. Comparisons of glucose uptake in the cranium was assessed using general linear model among controls, pPD, dnPD and mPD patients, as well as among mPD patients with different stages. Furthermore, effects of motor function, disease duration and dopaminergic medication on cranial glucose uptake were assessed using multiple linear regression.</p><p><strong>Results: </strong>The results demonstrated cranial hypermetabolism in clinically confirmed PD patients (dnPD and mPD patients) compared to HCs in the cranium, frontal, sphenoid and parietal bones (p < 0.05). In addition, mPD patients also demonstrated hypermetabolism in temporal and occipital bones compared to HCs (p < 0.05). However, this metabolic pattern was not observed in the prodromal individuals. Moreover, multiple linear regression identified fasting blood glucose as a positive modulator (β = 0.020 ~ 0.043, p < 0.05) and dopaminergic medication as a negative regulator (β=-1.207 × 10^-4~-9.482 × 10^-5, p < 0.005) of cranial glucose metabolic activity.</p><p><strong>Conclusion: </strong>The current study uncovered cranial metabolic abnormalities in PD, offering new perspectives and pathophysiological insights underlying bone-related comorbidities in PD.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of PET vascular activity score with Takayasu's arteritis angiographic progression.","authors":"Sifan Wu, Bing Wu, Lingying Ma, Mengdi Li, Xianting Sun, Shuhui Zhang, Hongcheng Shi, Lindi Jiang","doi":"10.1007/s00259-025-07348-2","DOIUrl":"10.1007/s00259-025-07348-2","url":null,"abstract":"<p><strong>Objective: </strong>Arterial wall Fluorodeoxyglucose (FDG) uptake can reflect vascular inflammation in Takayasu's arteritis (TAK); however, its association with vascular prognosis remains unclear. This study assessed the predictive efficacy of the PET vascular activity score (PETVAS) for vascular prognosis and whether FDG uptake in specific arterial territories was associated with angiographic progression in TAK.</p><p><strong>Methods: </strong>Patients with TAK from a prospective observational cohort who underwent ¹⁸F-FDG PET/CT and serological tests at baseline were included. Magnetic Resonance Angiography and/or Contrast-Enhanced Ultrasound were conducted at baseline and every six months during follow-up. The PETVAS was calculated. New/aggravated lesions were considered as angiographic progression.</p><p><strong>Results: </strong>The imaging evaluation included 1,353 arterial territories from 123 patients. The baseline PETVAS was positively correlated with Erythrocyte Sedimentation Rate (ESR), serum IL-6, and Platelet. Angiographic progression was noted in 45 patients (36.6%) with 72 territories (5.3%) during 30 (18-72) months of follow-up. Of these, 19 (42.2%) had baseline PETVAS > 15, including 84.2% (16/19) naïve cases and 78.9% (15/19) with ESR ≥ 30 mm/h. Multivariate Cox proportional hazards regression analysis adjusted for age and sex showed baseline PETVAS > 15 (HR 1.93; 95% CI, 1.01-3.68; p = 0.04) an independent predictor of angiographic progression.</p><p><strong>Conclusion: </strong>Baseline PETVAS > 15 was an independent predictor of angiographic progression in TAK. Baseline FDG uptake in specific arterial territories did not correlate with vascular progression. Our study provides a feasible PET/CT-based predictive marker for vascular progression in TAK and underscores the importance of regular imaging follow-up to monitor disease outcomes.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"4268-4280"},"PeriodicalIF":7.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144157509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}